Reason for change: reallocation of funds for R&D in the DTx product business, personnel investments, and office expansion. New disclosure targets include increases in R&D funding, increases in personnel investments, and increased office expansion costs. Expected impact going forward is minor.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4263","jir_company_name":"Sasmed Incorporated","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-09-17","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4263-20260917-01.pdf","jir_short_summary":"Reason for change: reallocation of funds for R&D in the DTx product business, personnel investments, and office expansion. New disclosure targets include increases in R&D funding, increases in personnel investments, and increased office expansion costs. Expected impact going forward is minor.","jir_summary":"### Rationale and Background\nBased on a board resolution, a portion of the funds allocated at listing has been reallocated. Reallocation of funds for clinical development of the DTx product business, recruitment and personnel costs, and office space expansion has been reallocated. Under the previous plan, funds were to be allocated primarily to R&D, with personnel investment and office expansion funded accordingly; however, in line with progress in clinical development and the need to strengthen the organization, the amounts for each item have been revised.\n\n### Details of Changes and Future Operating Policy\nWithin the updated approximate net amount of 3,444 million yen, funds will be allocated to (1) R&D: 1,916 million yen, (2) personnel investment: 1,240 million yen, and (3) office space expansion: 288 million yen. The remaining balance will be allocated as new development pipeline opportunities arise and clinical trial funding needs emerge; until payment timing is decided, funds will be managed in financial instruments with high safety.","jir_financial_highlights":"Research and development funding: 1,916 million yen (Updated: 1,916 million yen (before 1,167 million yen for the year ending June 2026, 435 million yen for the year ending June 2027, 314 million yen for the year ending June 2028 and beyond))\nHuman resources investment: 1,240 million yen (Updated: 1,240 million yen (before 816 million yen for the year ending June 2026, 311 million yen for the year ending June 2027, 113 million yen for the year ending June 2028 and beyond))\nOffice space expansion: 288 million yen (Updated: 288 million yen (before 154 million yen for the year ending June 2026, 116 million yen for the year ending June 2027, 18 million yen for the year ending June 2028 and beyond))","jir_category":"","jir_hashtags":"#Sasmed Incorporated, #ReallocationOfFunds, #Disclosure, #CapitalPolicy\/FundManagement","jir_key_figures":"R&D funding: 1,916 million yen\nHuman resources investment: 1,240 million yen\nOffice space expansion: 288 million yen","jir_meta_title":"\u3010Sasmed Incorporated\u3011Notice Regarding Reallocation of Funds Usage\uff5cSeptember 2026","jir_meta_description":"Sasmed Incorporated announces a reallocation of fund usage as of September 17, 2026. It presents new allocations for DTx development funding, workforce investments, and office expansion, and explains the forthcoming fund management policy.","jir_og_title":"\u3010Sasmed Incorporated\u3011Notice Regarding Reallocation of Funds Usage","jir_og_description":"Reassessment of allocations for DTx development funding, personnel investments, and office expansion. Disclosure of future fund management policy.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":58336,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"disclosure_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-114813","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n